Can Stress-Blockers help fight melanoma? early trial launches

NCT ID NCT05968690

Recruiting now Disease control Sponsor: Sarah Weiss Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tests whether adding two stress-blocking drugs—naltrexone and propranolol—to standard immunotherapy (ipilimumab and nivolumab) is safe for people with advanced melanoma. The study aims to find the best dose and check for side effects in 12 participants. If successful, it may lead to larger studies exploring a new way to improve cancer treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: naltrexone and propranolol
What this could lead to: If this combination is safe, it could point toward a new way to boost the immune system's fight against advanced melanoma by blocking stress signals.
What could go wrong: This is a very early phase 1 trial with only 12 people, so it's mainly checking safety, not effectiveness. The added drugs may cause side effects or not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma metastatic melanoma skin neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MELANOMA

Contacts and locations

Locations

Rutgers Cancer Institute of New Jersey
RECRUITING

New Brunswick, New Jersey, 08903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.